Abstract：Objective To investigate the impact of oral contrast agent for assisting in outlining the small bowel on pelvic volumetric modulated arc therapy (VMAT) dose in patients with cervical cancer. Methds Nine cervical cancer patients for postoperative radiotherapy underwent CT scans, and the target volumes and organs at risk including the small bowel were contoured. The VMAT plan was designed for each case. Then another plan was generated by re-calculating the radiation dose after changing the electron density of the small bowel. The first plan (plan A) was the conventional VMAT plan, and the second one (plan B) specified the electron density of the small bowel. Paired t-test was used to compare the dose distribution between the two plans. Results The D98, D50, conformity index, and homogeneity index of plans A and B were 4989.1 vs. 5000.1 cGy (P=0.026), 5208.6 vs. 5191.6 cGy (P=0.005), 0.766 vs. 0.765(P=0.920), and 0.081 vs. 0.074(P=0.055), respectively. The volumes of the small bowel receiving at least 30 Gy for plans A and B were 309.3 vs. 314.3 cm3(P=0.207), while bladder V45 of the two plans was 52.4% vs. 51.1%(P=0.168). To achieve the same prescribed dose, plan A and plan B needed 893.3 MU and 865.8 MU (P=0.093). Conclusions The contrast agent filling the small bowel does not lead to a significant increase in the pelvic VMAT dose in patients with cervical cancer after surgery.
Gu Wendong,Li Qilin,Gao Min et al. Impact of oral contrast agent for assisting in outlining small bowel on pelvic VMAT dose in patients with cervical cancer[J]. Chinese Journal of Radiation Oncology, 2014, 23(6): 472-474.
[1] Gay HA, Barthold HJ, O′Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy:a Radiation Therapy Oncology Group consensus panel atlas[J]. Int J Radiat Oncol Biol Phys,2012,83:353-362. [2] RTOG. A phase Ⅱ study of intensity modulated radiation therapy (IMRT) to the Pelvis+/chemotherapy for postoperative patients with either endometrial or cervical carcinoma (RTOG 0418)[DB/OL][2014-03-10]. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0418. [3] Small W Jr, Mell LK, Anderson P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer[J]. Int J Radiat Oncol Biol Phys,2008,71:428-434. [4] 秦颂兵,周菊英,龚唯,等.容积密度分配法剂量计算可行性研究[J].中华放射肿瘤学杂志,2013,22:247-249. [5] Jonsson JH, Karlsson MG, Karlsson M, et al. Treatment planning using MRI data:an analysis of the dose calculation accuracy for different treatment regions[J/OL]. Radiat Oncol,2010,5:62[2014-03-10]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909248/. [6] Weber DC, Rouzaud M, Miralbell R. Bladder opacification does not significantly influence dose distribution in conformal radiotherapy of prostate cancer[J]. Radiother Oncol,2001,59:95-97. [7] International commission on radiation units and measurements. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU Report 83[R]. Oxford:Oxford University Press,2010:1-106. [8] Kelly PJ, Mannarino E, Lewis JH, et al. Total dural irradiation:rapidArc versus static-field IMRT:a case study[J]. Med Dosim, 2012,37:175-181. [9] Quan EM, Li X, Li Y, et al. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment[J]. Int J Radiat Oncol Biol Phys,2012,83:1169-1178. [10] Kim HJ, Chang AR, Park YK, et al. Dosimetric effect of CT contrast agent in CyberKnife treatment plans[J/OL].Radiat Oncol,2013,8:244[2014-03-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829371/. [11] Amato E, Lizio D, Settineri N, et al. A method to evaluate the dose increase in CT with iodinated contrast medium[J].Med Phys,2010,37:4249-4256. [12] Ramm U, Damrau M, Mose S, et al. Influence of CT contrast agents on dose calculations in a 3D treatment planning system[J]. Phys Med Biol,2001,46:2631-2635.
2014, Vol. 23 
